Last reviewed · How we verify

NCT03441815

XC8 Safety, Tolerability and Pharmacokinetics in Healthy Volunteers

Completed Phase 1 Last updated 22 February 2018
What this trial tests

Phase 1 trial testing XC8 in Asthma in 28 participants. Completed in 7 July 2015.

Timeline
14 February 2015
Primary endpoint
7 July 2015
7 July 2015

Quick facts

Lead sponsorPHARMENTERPRISES LLC
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designsequential
Maskingdouble
Primary purposetreatment
Enrollment28
Start date14 February 2015
Primary completion7 July 2015
Estimated completion7 July 2015
Sites1 location across Russia

Drugs / interventions tested

Conditions studied

Sponsor

PHARMENTERPRISES LLC — full company profile →

Who can join

Adults 18 to 50, male only, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety and tolerability of increasing doses of XC8 after single and repeated oral administration in healthy volunteers. The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break. The primary objective of the study was to evaluate the safety and tolerability profile for XC8 after single and multiple administration based on the frequency and severity of adverse events and changes in vital signs, laboratory results, electrocardiography and results of the physical examination. The secondary objective of the study was to assess pharmacokinetics of XC8.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of XC8

Trials testing the same drug.

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other PHARMENTERPRISES LLC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03441815.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing